Loading company…
Vaxdyn develops vaccines targeting bacterial infections, including antibiotic-resistant infections.
Founded in 2011 in Sevilla, Spain, Vaxdyn develops vaccines for bacterial infections, including AcinetoVax for Acinetobacter baumannii and KapaVax for Pseudomonas aeruginosa and Klebsiella pneumoniae. Dr. Juan José Infante is the CEO. In September 2026, the company raised EUR 11 million in Series A funding from Biovance Capital, European Innovation Council, and Arcano Partners to begin Phase 1 clinical development of K-VAX.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in